These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

597 related articles for article (PubMed ID: 25999136)

  • 1. Impact of Chronic Statin Therapy on Postprocedural Contrast-Induced Nephropathy in Patients Undergoing Non-Emergent Percutaneous Coronary Intervention.
    Chanin JM; Yang DC; Haider MA; Swaminathan RV; Kim LK; Charitakis K; Tanoue M; Minutello RM; Gade CL; Singh HS; Bergman G; Wong SC; Feldman DN
    J Invasive Cardiol; 2015 Nov; 27(11):490-6. PubMed ID: 25999136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of statin pretreatment to prevent contrast-induced nephropathy and to improve long-term outcome in patients undergoing percutaneous coronary intervention.
    Patti G; Nusca A; Chello M; Pasceri V; D'Ambrosio A; Vetrovec GW; Di Sciascio G
    Am J Cardiol; 2008 Feb; 101(3):279-85. PubMed ID: 18237585
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statins for prevention of contrast-induced nephropathy in patients undergoing non-emergent percutaneous coronary intervention.
    Kandula P; Shah R; Singh N; Markwell SJ; Bhensdadia N; Navaneethan SD
    Nephrology (Carlton); 2010 Mar; 15(2):165-70. PubMed ID: 20470274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy] trial.
    Patti G; Ricottini E; Nusca A; Colonna G; Pasceri V; D'Ambrosio A; Montinaro A; Di Sciascio G
    Am J Cardiol; 2011 Jul; 108(1):1-7. PubMed ID: 21529740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions.
    Khanal S; Attallah N; Smith DE; Kline-Rogers E; Share D; O'Donnell MJ; Moscucci M
    Am J Med; 2005 Aug; 118(8):843-9. PubMed ID: 16084176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of long-term statin therapy on postprocedural myocardial infarction in patients undergoing nonemergency percutaneous coronary intervention.
    Gordin J; Haider A; Swaminathan RV; Kim LK; Minutello RM; Bergman G; Wong SC; Feldman DN
    Am J Cardiol; 2012 Nov; 110(10):1397-404. PubMed ID: 22858186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ratio of contrast volume to glomerular filtration rate predicts outcomes after percutaneous coronary intervention for ST-segment elevation acute myocardial infarction.
    Mager A; Vaknin Assa H; Lev EI; Bental T; Assali A; Kornowski R
    Catheter Cardiovasc Interv; 2011 Aug; 78(2):198-201. PubMed ID: 20949583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uric acid levels and the risk of Contrast Induced Nephropathy in patients undergoing coronary angiography or PCI.
    Barbieri L; Verdoia M; Schaffer A; Cassetti E; Marino P; Suryapranata H; De Luca G;
    Nutr Metab Cardiovasc Dis; 2015 Feb; 25(2):181-6. PubMed ID: 25315668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preprocedural statin use in patients undergoing percutaneous coronary intervention.
    Kenaan M; Seth M; Aronow HD; Naoum J; Wunderly D; Mitchiner J; Moscucci M; Gurm HS;
    Am Heart J; 2014 Jul; 168(1):110-6.e3. PubMed ID: 24952867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contrast-Induced Nephropathy After Percutaneous Coronary Intervention for Chronic Total Occlusion Versus Non-Occlusive Coronary Artery Disease.
    Demir OM; Lombardo F; Poletti E; Laricchia A; Beneduce A; Maccagni D; Slavich M; Giannini F; Carlino M; Margonato A; Cappelletti A; Colombo A; Azzalini L
    Am J Cardiol; 2018 Dec; 122(11):1837-1842. PubMed ID: 30292337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Statins for the Prevention of Contrast-Induced Nephropathy After Coronary Angiography/Percutaneous Interventions: A Meta-analysis of Randomized Controlled Trials.
    Liu YH; Liu Y; Duan CY; Tan N; Chen JY; Zhou YL; Li LW; He PC
    J Cardiovasc Pharmacol Ther; 2015 Mar; 20(2):181-92. PubMed ID: 25193735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of combination therapy of statin and N-acetylcysteine for the prevention of contrast-induced nephropathy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
    Park SH; Jeong MH; Park IH; Choi JS; Rhee JA; Kim IS; Kim MC; Cho JY; Sim DS; Hong YJ; Park HW; Kim JH; Ahn Y; Cho JG; Park JC; Kang JC
    Int J Cardiol; 2016 Jun; 212():100-6. PubMed ID: 27045874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statins and contrast-induced acute kidney injury with coronary angiography.
    Gandhi S; Mosleh W; Abdel-Qadir H; Farkouh ME
    Am J Med; 2014 Oct; 127(10):987-1000. PubMed ID: 24852935
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age, glomerular filtration rate, ejection fraction, and the AGEF score predict contrast-induced nephropathy in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.
    Andò G; Morabito G; de Gregorio C; Trio O; Saporito F; Oreto G
    Catheter Cardiovasc Interv; 2013 Nov; 82(6):878-85. PubMed ID: 23703775
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined impact of chronic kidney disease and contrast-induced nephropathy on long-term outcomes in patients with ST-segment elevation acute myocardial infarction who undergo primary percutaneous coronary intervention.
    Nakahashi H; Kosuge M; Sakamaki K; Kiyokuni M; Ebina T; Hibi K; Tsukahara K; Iwahashi N; Kuji S; Oba MS; Umemura S; Kimura K
    Heart Vessels; 2017 Jan; 32(1):22-29. PubMed ID: 27106917
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rosuvastatin versus atorvastatin to prevent contrast induced nephropathy in patients undergoing primary percutaneous coronary intervention (ROSA-cIN trial).
    Kaya A; Kurt M; Tanboğa IH; Işik T; Ekinci M; Aksakal E; Kaya Y; Topçu S; Sevimli S
    Acta Cardiol; 2013 Oct; 68(5):489-94. PubMed ID: 24283110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical impact of nephropathy induced by contrast medium in patients with acute myocardial infarction undergoing emergent coronary angiography].
    Jujo K; Yamaguchi J; Obayashi K; Suzuki K; Sekiguchi H; Nagashima M; Tsurumi Y; Kasanuki H
    J Cardiol; 2006 Jul; 48(1):9-16. PubMed ID: 16886495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Myocardial Infarct Size in Patients on Long-Term Statin Therapy Undergoing Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction.
    Marenzi G; Cosentino N; Cortinovis S; Milazzo V; Rubino M; Cabiati A; De Metrio M; Moltrasio M; Lauri G; Campodonico J; Pontone G; Andreini D; Bonomi A; Veglia F; Bartorelli A
    Am J Cardiol; 2015 Dec; 116(12):1791-7. PubMed ID: 26602070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Female gender and contrast-induced nephropathy in primary percutaneous intervention for ST-segment elevation myocardial infarction.
    Lucreziotti S; Centola M; Salerno-Uriarte D; Ponticelli G; Battezzati PM; Castini D; Sponzilli C; Lombardi F
    Int J Cardiol; 2014 Jun; 174(1):37-42. PubMed ID: 24698233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of receipt of chronic statin therapy before the onset of acute myocardial infarction: a retrospective study in patients undergoing primary percutaneous coronary intervention.
    Ishii H; Ichimiya S; Kanashiro M; Aoyama T; Ogawa Y; Murakami R; Amano T; Naruse K; Matsubara T; Murohara T
    Clin Ther; 2006 Nov; 28(11):1812-9. PubMed ID: 17213001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.